论文部分内容阅读
80例T2DM患者随机分成治疗组:早晚餐前应用诺和锐30皮下注射;对照组:早晚餐前半小时用诺和灵30R皮下注射。根据血糖情况调整胰岛素剂量直至达标。结果:两组均能有效的降低血糖,所用达标时间及胰岛素平均每日总量无明显差异,但治疗组早餐后30’,60’血糖较对照组降低明显,低血糖事件明显少于对照组。结论:诺和锐30较诺和灵30R更有效降低餐后血糖漂移,减少低血糖事件发生。
80 cases of T2DM were randomly divided into treatment group: noon and Rui 30 subcutaneous injection before and after meals; control group: half an hour before breakfast and evening meal with Norogen 30R subcutaneous injection. According to the blood glucose adjusted insulin dose until compliance. Results: The two groups were able to effectively lower blood glucose, the standard time and insulin daily total no significant difference, but the treatment group after breakfast 30 ’, 60’ blood glucose decreased significantly compared with the control group, the incidence of hypoglycemia was significantly less than the control group . CONCLUSIONS: NovoRed 30 is more effective in reducing postprandial blood glucose drift and reducing the incidence of hypoglycaemia than norrolate 30R.